The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound Study (AtheroRemoIVUS)
|ClinicalTrials.gov Identifier: NCT01789411|
Recruitment Status : Unknown
Verified February 2013 by Patrick W. Serruys, Erasmus Medical Center.
Recruitment status was: Active, not recruiting
First Posted : February 12, 2013
Last Update Posted : February 12, 2013
|Condition or disease||Intervention/treatment|
|Coronary Artery Disease||Other: Drawing blood samples Device: Coronary intravascular ultrasound imaging Device: Coronary near-infrared spectroscopy|
|Study Type :||Observational|
|Estimated Enrollment :||800 participants|
|Official Title:||The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound Study|
|Study Start Date :||November 2008|
|Estimated Primary Completion Date :||December 2013|
Drawing blood samples. Coronary intravascular ultrasound imaging. Coronary near-infrared spectroscopy.
Other: Drawing blood samples
Drawing blood samples from the arterial sheath prior to the standard coronary angiography procedureDevice: Coronary intravascular ultrasound imaging
Coronary intravascular ultrasound imaging of a non-culprit coronary artery.Device: Coronary near-infrared spectroscopy
Near-infrared spectroscopy imaging of a non-culprit coronary artery (in patient who are included in the AtheroRemo-NIRS substudy).
- Vulnerable plaque as determined by intravascular ultrasound [ Time Frame: cross-sectional (time of baseline coronary angiography, no follow-up) ]The primary objective is to correlate coronary plaque phenotype as determined by intravascular ultrasound with genetic profile and circulating biomarkers. Primary endpoint is the presence of vulnerable plaque as determined by intravascular ultrasound.
- Major adverse cardiac events [ Time Frame: 1-year follow-up ]The secondary objective is to assess the prognostic value of novel biomarkers and plaque phenotypes as determined by intravascular ultrasound and near-infrared spectroscopy. Secondary endpoint is 1-year incidence of major adverse cardiac events.
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01789411
|Study Chair:||Patrick W Serruys, MD, PhD||Erasmus MC|